Mubadala’s Kelix Bio Expands Footprint with Strategic Acquisition of Four Pharma Companies from Yas Holdings

Mubadala Investment Company has significantly enhanced its life sciences portfolio through its subsidiary, Kelix Bio, which has successfully acquired four pharmaceutical companies from Yas Holdings’ healthcare division, GlobalOne Healthcare Holdings. The acquisitions, which were announced on Monday, include Bioventure, Bioventure Healthcare, Gulf Inject, and Wellpharma.

While the financial details of the transactions remain undisclosed, Mubadala emphasized that these acquisitions will bolster Kelix Bio’s growth in the region and strengthen its presence in the UAE’s life sciences sector.

Overview of Acquired Companies:

• Bioventure: A biopharmaceutical firm with a global reach, Bioventure specializes in the commercialization of biotech and generic drugs. The company focuses on bringing cost-effective alternatives to branded pharmaceuticals to market once their original patents expire. Additionally, it engages in technology transfer and licensing.
• Bioventure Healthcare: This company manufactures soft gelatin capsules for both pharmaceutical and supplement products and is currently expanding its offerings to include oral solids and injectables.
• Gulf Inject: Recognized for its expertise in sterile fluid management therapy, Gulf Inject specializes in the administration and monitoring of intravenous fluids, parenteral therapy, and the production of healthcare manufacturing products.
• Wellpharma: Focused on producing intravenous therapies and dialysis equipment, Wellpharma caters to the healthcare needs of the UAE and the broader MENA region.

Mubadala’s acquisition of Kelix Bio was finalized in September after a definitive agreement was signed in March. The acquisition strategy aligns with the UAE government’s initiatives, such as Operation 300bn and the “Make it in the Emirates” campaign, aimed at bolstering the country’s manufacturing capabilities and promoting local production.

Dr. Bakheet Al Katheeri, CEO of the UAE Investments Platform at Mubadala, expressed optimism about the potential for growth, stating, “Kelix Bio and its assets are well-positioned for accelerated growth and will enable us to deliver on our ambition of creating a regional life sciences champion.”

This strategic move is expected to enhance affordable healthcare solutions in the Gulf Cooperation Council (GCC) and support the region’s ongoing investment in health and pharmaceutical industries.